Transaction Information
Intelligent Bio Solutions Inc. (Nasdaq: INBS) (the "Company") announced the closing of its previously announced underwritten public offering of units (the "Units") for gross proceeds of approximately $4.378 million prior to deducting underwriting discounts and commissions and offering expenses, including partial exercise of the underwriter's over-allotment option to purchase additional shares of common stock and warrants.
Ladenburg Thalmann & Co. Inc. acted as sole book-running manager in connection with this offering.
About Intelligent Bio Solutions Inc.
Intelligent Bio Solutions Inc. (the "Company") is a medical technology company delivering intelligent, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. This hygienic, and cost-effective system is designed to screen for recent use of drugs commonly found in the workplace, including opioids, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. For more information, visit www.ibs.inc.
The information and material presented is provided for informational purposes only and are not to be used or considered as an offer or the solicitation of an offer to sell or buy any securities mentioned herein.